Progression-free survival estimation of docetaxel-based second-line treatment for advanced non-small cell lung cancer: a pooled analysis from 18 randomized control trials

BackgroundLung cancer is the foremost cause of cancer-related death globally, with non-small cell lung cancer (NSCLC) accounting for 85–90% of cases. Targeted therapy is the most essential therapeutic option for NSCLC, other common treatments include radiation therapy, surgery, chemotherapy, and imm...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Chaithra N, Anisha Jain, Sahana C, Bhargav Shreevatsa, Saravanan Rajendrasozhan, Chandan Dharmashekar, Kuralayanapalya Puttahonnappa Suresh, Sharanagouda S. Patil, Pranav Singh, Prashant Vishwanath, Chandrashekar Srinivasa, Shiva Prasad Kollur, Chandan Shivamallu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-05-01
Edice:	Frontiers in Oncology
Témata:	non-small cell lung carcinoma lung neoplasms progression-free survival randomized control trials meta analysis
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1298786/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!